• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunogen Design for HIV-1 and Influenza

tetano

Editor, Senior Moderator
Biochim Biophys Acta. 2014 May 31. pii: S1570-9639(14)00148-4. doi: 10.1016/j.bbapap.2014.05.010. [Epub ahead of print]
Immunogen Design for HIV-1 and Influenza.
Rathore U1, Kesavardhana S1, Mallajosyula VV1, Varadarajan R2.
Author information
Abstract

Vaccines provide the most cost effective defence against pathogens. Although vaccines have been designed for a number of viral diseases, a vaccine against HIV-1 still remains elusive. In contrast, while there are excellent influenza vaccines, these need to be changed every few years because of antigenic drift and shift. The recent discovery of a large number of broadly neutralizing antibodies (bNAbs) and structural characterization of the conserved epitopes targeted by them presents an opportunity for structure based HIV-1 and influenza A vaccine design. We discuss strategies to design immunogens either targeting a particular antigenic region or focussing on native structure stabilization. This article is part of a Special Issue entitled: Recent advances in molecular engineering of antibody.

Copyright ? 2014. Published by Elsevier B.V.
KEYWORDS:

Glycosylation; Native trimer; Protein minimization; Stability; Vaccine

PMID:
24892211
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24892211
 
Back
Top Bottom